Aleniglipron produced up to 11.3% placebo-adjusted average weight loss at 36 weeks in a 2026 Phase 2b trial. It is a once-daily GLP-1 pill, but it is not a peptide.
The next big GLP-1 contest may not be one injection versus another. It may be injection versus pill. Aleniglipron, also called GSBR-1290, is one of the small-molecule candidates trying to make that change.
What the ACCESS study showed
The highest study dose produced the largest average change, and the curve had not clearly plateaued at week 36.
Format
A once-daily oral small molecule.
Best result
11.3% placebo-adjusted weight loss at 36 weeks.
Evidence stage
Phase 2b, with later-stage confirmation still needed.
What is aleniglipron?
Aleniglipron is an investigational small-molecule GLP-1 receptor agonist. “Small molecule” describes its chemical type. It does not mean the tablet or its effect is small.
This distinction is easy to miss because aleniglipron, semaglutide and tirzepatide all appear in the wider GLP-1 conversation.
- Aleniglipron is a small molecule that activates GLP-1 receptors.
- Semaglutide is a peptide that activates GLP-1 receptors.
- Tirzepatide is a peptide that activates GIP and GLP-1 receptors.
The receptor tells you which biological signal is being targeted. The molecule type affects how the material is made, tested, stored and delivered.
What did the 2026 aleniglipron trial find?
The ACCESS Phase 2b trial randomized 230 adults across 38 sites in the United States. Participants had obesity, or overweight plus at least one related health condition, and did not have diabetes.
They received placebo or once-daily aleniglipron. The active groups gradually increased to maintenance doses of 45, 90 or 120 mg.
| Daily maintenance group | Average weight change | Placebo-adjusted change |
|---|---|---|
| Aleniglipron 45 mg | -9.0% | -8.2% |
| Aleniglipron 90 mg | -10.7% | -9.8% |
| Aleniglipron 120 mg | -12.1% | -11.3% |
| Placebo | -0.8% | Reference |
At the 120 mg dose, the study estimated that:
- 86% of participants lost at least 5% of body weight;
- 70% lost at least 10%; and
- 38% lost at least 15%.
These were model-estimated response rates in a controlled trial. They are not a promise about what will happen to any individual.
Why do both 12.1% and 11.3% appear in reports?
Because they answer two slightly different questions.
- 12.1% was the estimated average change from the aleniglipron group’s own starting weight.
- 11.3% was the estimated difference after subtracting the change in the placebo group.
Both numbers are useful when labeled correctly. A headline that says “11.3% placebo-adjusted” is more precise than mixing the two.
The paper also reported an ongoing extension. At an interim look around week 56, the original groups had average reductions of 13.3%, 16.2% and 15.3%. Because participants had not all reached the same follow-up point, those extension data should be treated as an update rather than a final head-to-head result.
How does an oral small-molecule GLP-1 differ from a peptide?
Imagine two different keys opening the same type of lock. They may both activate a GLP-1 receptor, but the keys can be built very differently.
| Question | Aleniglipron | Peptide GLP-1 research materials |
|---|---|---|
| Molecule type | Small molecule | Peptide chain |
| Studied route | Oral tablet | Often injection; some oral formulations exist |
| Identity testing | Small-molecule analytical methods | Peptide sequence/mass and purity methods |
| Manufacturing | Chemical small-molecule process | Peptide synthesis or related peptide process |
| Directly interchangeable? | No | No |
This matters commercially. A buyer asking for “an oral GLP-1” has not yet written a complete specification. The request must identify the actual molecule, form, test methods, purity or assay limits, packaging and intended research use.
Read what are peptides? for the basic distinction, or see how peptides are made for a plain-English look at peptide production.
What side effects and discontinuations were reported?
The most common treatment-emergent events were gastrointestinal, including nausea, diarrhea, vomiting and constipation. The paper reported that these events were generally mild to moderate and became less frequent over time.
Across the aleniglipron groups, 10.4% stopped because of treatment-related events. Most of those discontinuations happened during earlier dose increases. The study did not report drug-induced liver injury.
That is a meaningful Phase 2b safety snapshot, not a final safety verdict. Rare events and long-term use require larger studies and longer follow-up.
What makes the result commercially important?
Recent community discussion about oral GLP-1s is not only about avoiding a needle. People are also asking about manufacturing scale, price, insurance, storage and access.
Small molecules may be attractive because they can be simpler to manufacture at large scale and do not need the same peptide production workflow. But a pill still has to prove that it works consistently, is tolerable and can be supplied at the required quality.
For peptide suppliers, the lesson is not that peptides are disappearing. It is that buyers will compare modality, documentation and supply reliability more closely as the GLP-1 category expands.
Aleniglipron vs oral ribupatide: the key difference
Both are once-daily oral GLP-1 research programs, but only one is a peptide.
For the category-level answer, see which oral GLP-1s are peptides and which are small molecules.
| Aleniglipron | Oral ribupatide | |
|---|---|---|
| Molecule type | Small molecule | Peptide |
| Receptor targets | GLP-1 | GLP-1 + GIP |
| Reported 2026 study | Phase 2b, 36 weeks | Phase 2, 26 weeks |
| Largest reported average | 11.3% placebo-adjusted | 11.9% from baseline under treatment-policy analysis |
Those percentages are not a fair “winner” comparison. The trials used different durations, populations, molecules and statistical definitions. The table is most useful for understanding the research landscape, not choosing treatment.
Read our oral ribupatide 2026 results for the peptide side of the story.
What the 2026 aleniglipron result means
Aleniglipron’s direct answer is: a daily oral small-molecule GLP-1 candidate produced up to 11.3% placebo-adjusted average weight loss at 36 weeks in Phase 2b. The 2026 data explain why oral GLP-1 programs are getting serious attention.
It is not a peptide and is not an approved product. Research buyers comparing the wider category should keep the molecule name, modality and current evidence stage separate instead of treating every GLP-1 product as the same material.
Review current semaglutide research specifications →
Sources and further reading
- Nature Medicine: ACCESS Phase 2b aleniglipron trial
- ClinicalTrials.gov: ACCESS study NCT06693843
- Publisher correction dated June 24, 2026
This article explains public research reported through August 6, 2026. It is educational and does not recommend an investigational product for personal use.
Frequently asked questions
What is aleniglipron?
Aleniglipron is an investigational once-daily oral small-molecule GLP-1 receptor agonist. It is also known as GSBR-1290 and is being developed for obesity treatment.
How much weight loss did aleniglipron produce?
In the 2026 ACCESS Phase 2b trial, placebo-adjusted average weight loss at week 36 was 8.2%, 9.8% and 11.3% across the 45, 90 and 120 mg groups.
Is aleniglipron a peptide?
No. Aleniglipron is a small molecule, not a peptide. It activates the GLP-1 receptor but differs in structure, manufacturing and delivery from peptide drugs such as semaglutide and tirzepatide.
Was aleniglipron tested as a pill?
Yes. The ACCESS study tested aleniglipron as a once-daily oral treatment, with doses gradually increased every four weeks during the 36-week double-blind period.
What were the most common aleniglipron side effects?
The most common events were gastrointestinal, including nausea, diarrhea, vomiting and constipation. The overall treatment-related discontinuation rate across aleniglipron groups was 10.4%.
Is aleniglipron approved?
No. Aleniglipron remains investigational. Phase 2b results support further study but do not make it an approved product or establish its long-term benefit-risk profile.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →